IDO1 Inhibitor Design for Selective Binding and Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic strategies for cancer treatment lack effective inhibitors of indoleamine 2,3-dioxygenase-1 (IDO1), which is crucial for modulating immune responses in tumors and associated with various diseases, including cancer and neurological disorders.
Innovation Solution
Development of specific compounds, such as those represented by Formulas I and Ib, which act as inhibitors of IDO1 by binding to its active site, thereby modulating its activity and treating disorders related to abnormal IDO1 expression or dysregulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IDO1 is inhibited to treat cancer and neurological disorders, then therapeutic efficacy is improved, but selectivity and off-target effects become critical concerns
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (halogen substituents at positions 4 and 5 of the indole ring, particular R1 groups) that create localized interaction patterns with IDO1's active site. This localized molecular design enables selective binding to IDO1 while avoiding off-target proteins, resolving the contradiction between therapeutic efficacy and harmful off-target effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters (halogen type: F, Cl, Br; positions; R1 group identities) to optimize the balance between IDO1 inhibition potency and selectivity. These parameter modifications allow fine-tuning of the inhibitor's interaction with IDO1's heme-containing active site, achieving high therapeutic efficacy while minimizing off-target effects.
2Ease of operation
If small molecule inhibitors are developed for IDO1, then drug delivery and bioavailability are improved, but molecular complexity and synthesis difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core indole structure, halogen substituents (F, Cl, or Br) at specific positions, and variable R1 groups (cycloalkyl, heterocycloalkyl, aryl, or heteroaryl). This segmented molecular architecture simplifies synthesis by allowing modular assembly of these segments while maintaining the complex three-dimensional structure needed for effective IDO1 inhibition and good drug delivery properties.
Data Source
AI summary
Inhibition of indoleamine 2,3-dioxygenase (IDO1) is an attractive immunotherapeutic approach for the treatment of a variety of cancers. Dysregulation of this enzyme has also been implicated in other severe diseases such as Alzheimer's disease and arthritis. Small molecule inhibitors of Formula (Ia) and (Ib) of IDO, their synthesis, and uses thereof are provided.